Aradigm’s inhaled antibiotic fails late-stage study Anthrax, Antibiotics, Bioterrorism, Bioterrorism Infections, Clinical Trials, Cystic Fibrosis, Fast Track Designation, Health, Inhaled Tularemia, Lung Infections, Melioidosis, Non-Cystic Fibrosis Bronchiectasis (non-CF BE), Orphan Drugs, Pneumonic Plague, Q fever, R&D, Shares, Smoking Aradigm Corp.’s inhaled antibiotic for a rare, incurable disorder affecting the lungs failed a late-stage study, sending the company’s shares down in premarket trading. Read more December 1, 2016/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2016-12-01 09:39:332016-12-02 11:34:51Aradigm's inhaled antibiotic fails late-stage study
